A Phase I/II Trial of WT1-Specific TCR Gene Therapy for Patients with Acute Myeloid Leukemia and Active Disease Post-Allogeneic Hematopoietic Cell Transplantation: Skewing Towards NK-Like Phenotype Impairs T Cell Function and Persistence.

In this Phase I/II clinical trial, scientists evaluated safety, persistence and efficacy of Epstein-Barr virus- or Cytomegalovirus-specific Tumor Antigen 1-specific T-cell receptor in fifteen patients with active acute myeloid leukemia post-hematopoietic cell transplantation.